Forage | $40,000,000 | (Jun 5, 2026)
InCharge Energy | $46,000,000 | (Jun 5, 2026)
Oak Hill Bio | $32,500,000 | (Jun 5, 2026)
A-Alpha Bio
United States
- Seattle, Washington
- 26/07/2023
- Series A
- $22,400,000
At A-Alpha Bio, we aim to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions.
Current approaches for measuring protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. AlphaSeq is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. We are seeking industry partnerships to evaluate the use of AlphaSeq for a variety of drug development applications.
A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.
- Industry Biotechnology Research
- Website https://www.aalphabio.com/
- LinkedIn https://www.linkedin.com/company/aalphabio/
Related People
David YoungerCo Founder
United States -
Seattle, Washington
A-Alpha Bio partners with pharmaceutical companies to discover and optimize high-impact therapeutics.
ZutaCore | $100,000,000 | (Jun 5, 2026)
Terra AI | $20,000,000 | (Jun 5, 2026)
Town | $55,000,000 | (Jun 5, 2026)
Lassie | $35,000,000 | (Jun 5, 2026)
OFFROAD | $7,000,000 | (Jun 5, 2026)
Shifters | $10,200,000 | (Jun 5, 2026)
Quobly | $133,545,475 | (Jun 5, 2026)
Scispot | $8,000,000 | (Jun 5, 2026)
Scotch | $20,000,000 | (Jun 5, 2026)